Insulin Delivery Devices Market Size, Share, Growth, Report 2026 To 2035

Insulin Delivery Devices Market Size, Growth, Forecast 2026 to 2035

The global insulin delivery devices market size was valued at USD 34.40 billion in 2025 and is expected to be worth around USD 58.52 billion by 2035, growing at a compound annual growth rate (CAGR) of 5.46% over the forecast period from 2026 to 2035. The increasing rate of diabetes across the world, as well as the aging population, is fueling the insulin delivery devices demand. These devices have propelled their usage because they enhance the quality of life of the patients, administration of insulin in the most accurate manner and reduce hospitalization expenses. The development of biocompatible and bioresorbable materials coupled with the advancement of minimally invasive technologies has increased device safety, efficacy, and longevity, which further increased the growth of the market.

Moreover, smarter insulin delivery gadgets with attached biosensors are changing the way diabetes is dealt with. They allow real-time tracking, long-distance monitoring, and individual adjustment of treatment and are not limited to the hospital environment but are also used in outpatient clinics and at home. This enhances the access to patients and also reduces the total cost of healthcare. The next generation of diabetes treatment will involve insulin delivery devices as they will be the key to the better efficiency, outcomes, and transition toward more personalized and cost-effective treatment.

Report Highlights

• By Region, North America led the insulin delivery devices market with a 42.7% revenue share, supported by advanced healthcare infrastructure, high diabetes prevalence, favorable reimbursement frameworks, and rapid adoption of smart and connected insulin delivery technologies.
• By Type, insulin pens captured a 38.5% revenue share, driven by their ease of use, portability, dosing accuracy, and strong patient acceptance. The growing availability of smart and reusable pens with dose-memory and connectivity features is further supporting adoption.
• By Application, Type II diabetes dominated with a 61.4% revenue share, reflecting the substantially larger patient population and the increasing need for injectable insulin therapy as the disease progresses.
• By End User, home care accounted for the largest share at 52.1%, supported by the growing preference for self-administered insulin therapy. Connected devices, telemonitoring, and simplified interfaces are also making remote diabetes management more accessible.
• By Distribution Channel, retail pharmacies held a 45.3% revenue share, benefiting from broad geographic accessibility, established supply chains, pharmacist support, and convenient refill services for insulin pens, needles, and syringes.

Insulin Pen and Smart Pen Adoption Statistics

• The estimated penetration of insulin pen use is over 50% of insulin users globally in most developed markets, showing the industry’s continuing movement toward improved and more discreet insulin delivery devices at the expense of the older vial-and-syringe combination devices. 
• Approximately 60% of all insulin users were using pens by the end of the decade in the U.S., versus much lower penetration in previous decades. 
• As an example of rapid evolution, this figure rose from roughly 8% to over 50% for Medicare beneficiaries between 2006 and 2016, showing how quickly many older insulin patients switched away from vial-and-syringe and towards pen delivery of their diabetes medication. 
• Similar trends can be observed across developed markets, where majority of insulin injections are delivered via pens in markets such as the U.K., Germany and France, countries which, due to good market access and reimbursement, are leaders in the adoption of disposable and reusable insulin pen device technologies. 
• Given more than 20 million people actively used Novo Nordisk diabetes-care products globally in 2024, we can deduce there is now a significant patient installed base with devices, which could also leverage improved insulin-pen systems. 
• According to results from a real-world study with 94 people who used the NovoPen 6 connected pen atopic skin product, over 90% of individuals remained engaged with the innovative device after 6 months, demonstrating significant patient adherence in learning the associated, unique dose tracking and diabetes recording feature and how easy it was to record medication events accurately. 
• Another real-world evidence on smart-pens indicated over 90% of people reported improved confidence with tracking the correct administration of doses with a smart device, minimizing any events of missed or doubled insulin doses. 
• Over 20–30% of insulin injections in some treated populations have been noted to be missed or taken at inconsistent times, this means clearly there is a space in the market for a device which helps eliminate or reduces some of these issues automatically. 
• With roughly 7.2 million CGM users in the United States as of 2024, as reported by figures shared by American Diabetes Association, an entire connected-diabetes infrastructure is beginning to emerge that the smart insulin pen solution can be integrated into.

Country-level Analysis

Recent Trends

• Advances in Closed Loop ‘Artificial Pancreas’ Systems: Adoption of closed loop systems automates insulin delivery through continuous monitoring of blood glucose levels. In April 2025, further advancements in hybrid closed loop devices were approved by regulators. This device represents a significant move towards completely automated management of diabetes, minimizing remaining manual adjustments, and enhancing overall glycemic control.
• Wearable Insulin Patches: Adoption of wearable insulin patches is increasing as they facilitate uninterrupted insulin delivery. Next-generation patches with integrated glucose sensors will now provide real-time glucose monitoring. Introduced together with insulin patches in July 2025, these innovations will help in improve patient adherence to diabetes management.
• Advances in Material Sciences: Improvements to biocompatible and bioresorbable glucose implants and coatings will improve patient safety by reducing the duration of implantable glucose delivery devices and reducing implants with the potential for infection for insulin pumps and patient ease for long term insulin implants in the body. Long term implants of insulin pumps combined with bioresorbable glucose implants and coatings will improve patient comfort and safety.

Report Scope

Market Dynamics

Market Drivers

• Rising Diabetes Prevalence: Growing incidences of type 1 and type 2 diabetes globally enhances the need for more innovative insulin delivery systems. As of June 2025, research indicated a growing adoption of smart insulin pumps and wearable technologies for more efficient glucose monitoring. The aim is to offer more precise treatment and alleviate the daily load of managing diabetes.
• Shift to Home & Outpatient Care: The momentum of home-based and outpatient diabetes care is growing. As of July 2025, a number of hospitals documented the effective adoption of remote insulin management systems, whereby smart devices allow clinicians to supervise glucose control from a distance. This system lessens the need for regular hospital appointments and facilitates greater patient adherence to treatment.

Market Restraints

• Regulatory Hurdles: The approval and compliance processes for insulin delivery devices require a considerable investment of time and effort. Manufacturers expressed that a predominant market-entry challenge for next-generation automated and wearable devices pertains to the sluggish pace of regulatory reviews, as highlighted in May 2025.
• Insurance & Reimbursement Limitations: Inadequate and inconsistent insurance reimbursement policies disproportionately limit insulin delivery systems. Specifically, the reimbursement obstacles described by patient advocacy groups and clinicians in July 2025 severely limit access to advanced insulin delivery systems used in outpatient and home care.

Market Challenges

• High Device Costs: The more sophisticated insulin delivery devices become—having integrated sensors, wireless technology, and automation systems, among other features—means more costly development and production. By August 2025, hospitals in some areas noted the cost of implementing next-generation insulin pumps as the most significant barrier to broader patient adoption.
• Technical Complexity and Training Needs: The modern insulin delivery devices and systems are also more complicated, creating a greater need for patient training. In July 2025, diabetes care programs using AI-enabled insulin pumps cited the need for training structured around the potential for misuse in order to ensure the appropriate management of glucose levels.

Market Opportunities

• Managed Access to Care: Personalization in therapy is made possible by AI-powered therapy systems for insulin delivery. Systems that improve outcomes and minimize hypoglycemic events by adapting insulin dosing to a patient's individual glucose pattern were piloted in hospitals in June 2025.
• Advancements in Wearable Technology: Innovative designs in Continuous and implantable devices offered insulin delivery systems advancements in portability and ease of use. In May 2025, a wearable insulin patch that was part of a clinical trial showed increased patient adherence and satisfaction which was a great improvement compared to traditional insulin delivery systems.
• Analytics in Care Delivery: Proactive interventions are made possible due to the integration of CGMs and advanced predictive systems. In July 2025, hospitals employing AI systems for glucose monitoring performed proactive interventions by adjusting insulin levels to prevent identified critical glucose trends.

Regional Analysis

The insulin delivery devices market is segmented into several key regions: North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa). Here’s an in-depth look at each region.

Why does North America dominate the insulin delivery devices market?

North America has been dominating the market because of its excellent healthcare system, prevalence rates of diabetes, and its adoption of the sophisticated technologies. In April 2025, the FDA of the United States gave a next-generation closed-loop insulin pump that enables automated insulin delivery with minimal manual interventions to enhance the safety of patients and the level of glycemic regulation. Moreover, AI-enabled solutions are being deployed in hospitals and outpatient clinics in the U.S. and Canada to identify and measure the functionality of the devices, to optimize the insulin dosage or to minimize hospital readmissions. High reimbursement policies and the overall awareness of patients also ensure that North America remains the most profitable market in terms of insulin delivery devices.

Europe Market Trends

The market development in Europe is influenced by strict regulatory requirements, the boost in demand among patients who require the use of minimal invasive devices, and adoption of smart technology. In June 2025, insulin pump training programs in Germany and France were launched with the help of robotics and allowed clinicians to improve device management and patient care. The U.K, Italy, and the Netherlands, among others are adopting bio-compatible and biocompatible insulin pens and smart wearable pumps that maximize therapy and do not compromise patient safety. The emphasis by Europe on regulatory compliance, new materials and superior device designs makes Europe a market leader in the effective and safe insulin delivery solutions.

Why is Asia-Pacific witnessing strong growth in the insulin delivery devices market?

Asia-Pacific is witnessing strong growth due to the aging population, growing access to healthcare, and a robust governmental support. Japan, South Korea and India introduced nationwide projects in July 2025 to supply cheap insulin pumps and smart pens to diabetics, especially the elderly. In the meantime, there is investment in China in the local production of smart insulin delivery devices with AI-enabled monitoring in order to decrease reliance on importation. Affordability, innovation, and rising access to healthcare are all contributing to the sudden rise in APAC insulin delivery market.

Insulin Delivery Devices Market Share, By Region, 2025 (%)

LAMEA Market Trends

Insulin delivery devices adoption is yet to be realized in LAMEA where most of the growth has been experienced in urban centers and through private healthcare facilities. In August 2025, Brazil began a government subsidies initiative to subsidize insulin pumps to patients with low incomes to enhance access. In Middle East, some of the countries such as Saudi Arabia and UAE are also investing in high-level diabetes care facilities which provide continuous glucose monitoring and automated insulin delivery systems. South Africa is testing mobile health units in Africa with remote insulin devices to follow up on access in rural locations. Although the adoption is still at an initial level, there are government efforts that are focused on ensuring the establishment of the long-term growth of the markets.

Segmental Analysis

Type Analysis

Insulin Pumps: The biggest segment of the products is insulin pumps, which provides continuous insulin infusion subcutaneously and a precise glucose management. Their capability to decrease hypoglycemic episodes and enhance quality of life is increasing its adoption. In April 2025, Medtronic launched its next-generation MiniMed 780G in the U.S. with auto-correction boluses and Bluetooth connectivity, as the trend toward smarter, AI-assisted pumps.

Insulin Pens: Insulin pens are gaining much acceptance due to their convenience, portability and ease of use over syringes. In June 2025, Novo Nordisk released its smart reusable insulin pen in Europe, which transmits dosing data to mobile applications to allow patients and clinicians to better track adherence.

Insulin Pen Needles: This category assists with adoption of pen needles and provides ultra-thin and painless designs. In May 2025, Becton Dickinson (BD) announced its rollout of its new BD Nano 2ndGen pen needles in Asia-Pacific to provide increased comfort and reduce dosing errors.

Insulin Jet Injectors: Jet injectors are a niche product but they provide needle-free administration to needle-shy patients. In March 2025, PharmaJet widened its needle-free injector partnerships in diabetic clinical research in Canada and indicated more research focus in this segment.

Insulin Syringes: Old fashioned syringes are still considered applicable in low-income areas, as they are cheap. In January 2025, India’s Hindustan Syringes and Medical Devices increased the production of low cost insulin syringes by 20 times to cater to the increasing domestic demand.

Others: New wearable patch pumps and micro-implants are transforming this space. Insulet also published a new Omnipod patch pump in July 2025 in Japan that is capable of delivering insulin tubelessly and discreetly.

Application Analysis

Type I Diabetes: This category prevails since patients with Type I diabetes rely on external insulin measurements throughout their lives. A big trial with hybrid closed-loop pump systems approved by the Juvenile Diabetes Research Foundation (JDRF) in the U.S. in February 2025, shows the increased use of advanced technologies among Type I patients.

Insulin Delivery Devices Market Share, By Application, 2025 (%)

Type II Diabetes: An increasing proportion with the obesity pandemic in the world and sedentary lifestyle. The move to devices in the management of Type II, even in late disease, was emphasized by the Indian Council of Medical Research in May 2025, as it announced a national effort to offer subsidized insulin pens and pumps to Type II patients in urban areas.

End User Analysis

Home Care: This segment is operated by home care because patients can inject insulin through pumps, pens, and wearables. In July 2025, Dexcom collaborated with Abbott in the U.S. to combine continuous glucose monitoring (CGM) and home insulin delivery devices so that real-time adjustments can be made remotely.

Hospitals & Clinics: Hospitals are essential in terms of initial diagnosis, education, and high-tech device-assisted treatment. According to the involvement of hospitals in the pioneering therapies, Cleveland Clinic started to provide implantable insulin delivery trials to in-patients with brittle diabetes in April 2025.

Insulin Delivery Devices Market Share, By End User, 2025 (%)

Others: Community health facilities and non-governmental organizations help in managing diabetes in areas with resources restrictions. In March 2025, Médecins Sans Frontières increased its pilot program in Sub-Saharan Africa to provide low-cost insulin syringes and training of rural diabetic patients.

Distribution Channel Analysis

Online Sales: This is the fastest growing channel owing to the convenience and direct-to-patient supply models. Amazon Pharmacy has delivered insulin pump and pen needles nationwide in June 2025, which makes sure that diabetic patients can gain access to the deliveries at their doorstep.

Hospital Pharmacies: This is also a critical setting because majority of prescriptions of the pumps and devices are made in hospitals. Mayo Clinic began to integrate smart insulin pen data in EHRs of patients in May 2025, connecting the prescription and monitoring.

Insulin Delivery Devices Market Share, By Distribution Channels, 2025 (%)

Retail Pharmacies: Retail chains serve the purposes of continuing prescribed drugs and equipment refills. In 2025, in the U.S., Walgreens extended its same-day delivery service of insulin pens and pumps to make it more accessible.

Other Clinics: There are small outpatient centers and small privately owned clinics that are used as distribution outlets. In April 2025, Singapore-based private diabetes clinics embraced in-clinic dispensing of linked insulin pens and patients who needed the therapy could commence therapy immediately.

Insulin Delivery Devices Market Top Companies

• Novo Nordisk A/S
• Wockhardt Ltd.
• Medtronic
• Roche Holding AG
• Abbott Laboratories
• Sanofi
• Eli Lilly and Company
• Biocon Ltd.
• Ypsomed AG
• Becton, Dickinson and Company

Recent Developments

• In August 2025, The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Sanofi’s teplizumab, a humanized monoclonal antibody targeting CD3, to delay the onset of symptomatic, Stage III autoimmune type 1 diabetes (T1D) in adults and pediatric patients aged eight and older with Stage II T1D, making the UK the first European country with such approval; teplizumab works by training the immune system to protect pancreatic beta cells, enabling the pancreas to keep producing insulin and letting eligible patients postpone insulin injections and intensive disease management by up to three years, providing time to prepare for progression rather than facing a sudden diagnosis.

Market Segmentation

By Type

• Insulin Pumps
  
  • Patch Pumps
  • Tethered Pumps
• Insulin Pens
  
  • Reusable
  • Disposable
• Insulin Pen needles
  
  • Standard Pen Needles
  • Safety Pen Needles
• Insulin Jet Injectors
• Insulin Syringes
• Others

By Distribution Channels

• Online Sales
• Hospital Pharmacies
• Retail Pharmacies
• Other Clinics

By Application

• Type I Diabetes
• Type II Diabetes 

By End User

• Home Care
• Hospitals & clinics
• Others

By Region

• North America
• APAC
• Europe
• LAMEA